Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
Inhibikase Therapeutics (Nasdaq: IKT) has announced significant leadership changes effective February 14, 2025. Mark Iwicki, with over 30 years of biopharmaceutical industry experience, has been appointed as CEO, replacing founder Dr. Milton H. Werner. Additionally, Amit Munshi has been named Chair of the Board, succeeding Roberto Bellini, who will continue as a director.
The company granted Iwicki substantial inducement awards, including options to purchase up to 15,061,377 shares total, with various vesting conditions. These awards were granted outside the company's 2020 Equity Incentive Plan as a material inducement to his employment.
The new leadership team will focus on advancing IkT-001Pro through clinical development, particularly for PAH (Pulmonary Arterial Hypertension) treatment, leveraging $110 million in proceeds from October financing.
Inhibikase Therapeutics (Nasdaq: IKT) ha annunciato importanti cambiamenti nella leadership a partire dal 14 febbraio 2025. Mark Iwicki, con oltre 30 anni di esperienza nell'industria biofarmaceutica, è stato nominato CEO, sostituendo il fondatore Dr. Milton H. Werner. Inoltre, Amit Munshi è stato nominato Presidente del Consiglio, succedendo a Roberto Bellini, che continuerà a servire come direttore.
L'azienda ha concesso a Iwicki significativi premi di indennità, inclusi diritti di opzione per acquistare fino a 15.061.377 azioni totali, con varie condizioni di maturazione. Questi premi sono stati concessi al di fuori del Piano di Incentivazione Azionaria 2020 dell'azienda come incentivo materiale per il suo impiego.
Il nuovo team di leadership si concentrerà sull'avanzamento di IkT-001Pro attraverso lo sviluppo clinico, in particolare per il trattamento della PAH (Ipertensione Arteriosa Polmonare), sfruttando 110 milioni di dollari provenienti dal finanziamento di ottobre.
Inhibikase Therapeutics (Nasdaq: IKT) ha anunciado cambios significativos en el liderazgo a partir del 14 de febrero de 2025. Mark Iwicki, con más de 30 años de experiencia en la industria biofarmacéutica, ha sido nombrado CEO, reemplazando al fundador Dr. Milton H. Werner. Además, Amit Munshi ha sido nombrado Presidente de la Junta, sucediendo a Roberto Bellini, quien continuará como director.
La compañía otorgó a Iwicki premios de inducción sustanciales, incluidas opciones para comprar hasta 15.061.377 acciones en total, con diversas condiciones de adquisición. Estos premios se otorgaron fuera del Plan de Incentivos de Capital 2020 de la empresa como un incentivo material para su empleo.
El nuevo equipo de liderazgo se enfocará en avanzar en IkT-001Pro a través del desarrollo clínico, particularmente para el tratamiento de la PAH (Hipertensión Arterial Pulmonar), aprovechando 110 millones de dólares de los ingresos de la financiación de octubre.
Inhibikase Therapeutics (Nasdaq: IKT)는 2025년 2월 14일부터 주요 리더십 변경을 발표했습니다. Mark Iwicki는 30년 이상의 생물 제약 산업 경험을 바탕으로 CEO로 임명되었으며, 창립자인 Dr. Milton H. Werner를 대체하게 됩니다. 또한, Amit Munshi는 Roberto Bellini의 후임으로 이사회 의장으로 임명되었습니다. Bellini는 이사로 계속 활동할 것입니다.
회사는 Iwicki에게 15,061,377주를 구매할 수 있는 옵션을 포함한 상당한 유인 보상을 제공했습니다. 이 보상은 다양한 조건에 따라 부여되었으며, 기업의 2020년 주식 인센티브 계획 외부에서 그의 고용을 위한 중요한 유인으로 제공되었습니다.
신임 리더십 팀은 10월 자금 조달로 확보한 1억 1천만 달러를 활용하여 PAH(폐동맥 고혈압) 치료를 위한 임상 개발을 통해 IkT-001Pro를 발전시키는 데 집중할 것입니다.
Inhibikase Therapeutics (Nasdaq: IKT) a annoncé d'importants changements au sein de sa direction, effectifs à partir du 14 février 2025. Mark Iwicki, fort de plus de 30 ans d'expérience dans l'industrie bio-pharmaceutique, a été nommé PDG, remplaçant ainsi le fondateur Dr. Milton H. Werner. De plus, Amit Munshi a été nommé Président du Conseil, succédant à Roberto Bellini, qui continuera à siéger en tant que directeur.
L'entreprise a accordé à Iwicki des primes d'incitation substantielles, y compris des options d'achat de jusqu'à 15.061.377 actions au total, avec diverses conditions d'acquisition. Ces primes ont été accordées en dehors du Plan d'Incentives en Actions 2020 de l'entreprise comme un incitatif matériel à son emploi.
La nouvelle équipe de direction se concentrera sur l'avancement d'IkT-001Pro à travers le développement clinique, en particulier pour le traitement de la PAH (Hypertension Artérielle Pulmonaire), en tirant parti de 110 millions de dollars provenant du financement d'octobre.
Inhibikase Therapeutics (Nasdaq: IKT) hat bedeutende Änderungen in der Führung bekannt gegeben, die am 14. Februar 2025 wirksam werden. Mark Iwicki, der über 30 Jahre Erfahrung in der biopharmazeutischen Industrie verfügt, wurde zum CEO ernannt und ersetzt den Gründer Dr. Milton H. Werner. Darüber hinaus wurde Amit Munshi zum Vorsitzenden des Boards ernannt und tritt die Nachfolge von Roberto Bellini an, der weiterhin als Direktor tätig sein wird.
Das Unternehmen hat Iwicki erhebliche Anreizvergütungen gewährt, einschließlich Optionen zum Kauf von insgesamt bis zu 15.061.377 Aktien, die verschiedenen Vesting-Bedingungen unterliegen. Diese Vergütungen wurden außerhalb des Equity Incentive Plans 2020 des Unternehmens als wesentlicher Anreiz für seine Anstellung gewährt.
Das neue Führungsteam wird sich darauf konzentrieren, IkT-001Pro durch die klinische Entwicklung voranzubringen, insbesondere zur Behandlung von PAH (pulmonale arterielle Hypertonie), wobei 110 Millionen Dollar aus der Finanzierung im Oktober genutzt werden.
- Secured $110 million in financing from October funding round
- Appointed experienced industry veteran with PAH expertise as CEO
- Moving forward with Phase 2b clinical trial for IkT-001Pro
- Significant stock dilution potential from 15+ million new stock options granted to new CEO
-- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases --
-- Amit Munshi Appointed Chair of the Board of Directors --
BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief Executive Officer, replacing Dr. Milton H. Werner, founder of Inhibikase, effective February 14, 2025. Additionally, effective February 14, 2025, Amit Munshi, a member of the Board of Directors of the Company (the “Board”) and veteran biopharmaceutical industry executive with deep experience in PAH, has been appointed as the independent Chair of the Board, replacing Roberto Bellini. Mr. Bellini will continue to serve as a director of the Company.
“We are pleased to have a highly respected and accomplished leader like Mark, join Inhibikase as our new CEO,” said Mr. Bellini, current Chair of the Board. “Mark brings to Inhibikase a strong track record of operational excellence and shareholder value creation. I am also very excited that Amit has agreed to take over the Chair role at this pivotal moment for the Company. This leadership team is well positioned to drive Inhibikase forward, and I look forward to supporting Mark and Amit as a Board member.”
“I am very pleased to join Inhibikase at such a promising moment in its development,” said Mr. Iwicki. “I have spent a great deal of my career working on cardiovascular diseases, and it is clear there is a strong opportunity for Inhibikase to make a meaningful difference for patients suffering from PAH. I am impressed with the profile of IkT-001Pro, and believe we are well positioned to successfully advance IkT-001Pro though clinical development, as new treatment options are critical to patients given the significant unmet needs in the management of PAH.”
“I want to express my excitement to serve as Chair of the Board at this transformative moment for the Company,” said Mr. Munshi. “Inhibikase is poised to create a fundamental shift in the lives of patients suffering from PAH. We are pleased to advance IkT-001Pro in a Phase 2b clinical trial and deliver for our shareholders on IKT-001Pro, leveraging the
Mr. Iwicki succeeds Dr. Milton H. Werner, founder of Inhibikase. Mr. Munshi succeeds Mr. Bellini as Chairman of Board of Directors and will continue to serve on the Inhibikase Board of Directors. Both appointments are effective as of February 14, 2025.
Mr. Iwicki has more than 30 years of biopharmaceutical industry experience. He was previously Chief Executive Officer of KALA BIO. Mr. Iwicki currently serves as the Chair of board of directors of KALA BIO and also serves on the boards of directors of Nimbus, Akero Therapeutics, Third Harmonic Bio, Q32 Bio and Merus. He previously served as President and Chief Executive Officer of Civitas Therapeutics and Sunovion Pharmaceuticals Inc. He was also President and Chief Executive Officer of Blend Therapeutics, and President and Chief Operating Officer at Sepracor. Earlier in his career, he was Vice President and Business Unit Head at Novartis Pharmaceuticals Corporation and held management positions at Astra Merck Inc. and Merck & Co. He previously served on the board of Aimmune Therapeutics. Mr. Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University.
Amit Munshi is a 30-year industry veteran who is currently Chief Executive Officer of Orna Therapeutics and former President, Chief Executive Officer and board member of ReNAgade Therapeutics. Previously, Mr. Munshi served as President and CEO of Arena Pharmaceuticals Inc., which was subsequently sold to Pfizer, Inc. Previously, Mr. Munshi served as President and Chief Executive Officer of Epirus Biopharmaceuticals and Percivia LLC, and prior to that, was a co-founder and served as Chief Business Officer of Kythera Biopharmaceuticals. Earlier in his career, Mr. Munshi held multiple leadership positions at Amgen, including General Manager, Nephrology Europe. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University.
Inducement Awards
In connection with Mr. Iwicki’s appointment as Chief Executive Officer, the Company granted Mr. Iwicki inducement awards consisting of (i) non-qualified stock options to purchase up to 6,168,148 shares of the Company’s common stock (the “Common Stock”) with an exercise price equal to the closing price of the Common Stock as reported on the Nasdaq Capital Market on February 14, 2025 (the “Closing Price”), which shall vest in 48 substantially equal monthly installments, (ii) non-qualified stock options to purchase up to 6,837,180 shares of Common Stock with an exercise price equal to the Closing Price, which shall vest in 48 substantially equal monthly installments and become exercisable in an amount proportional to the number of exercised Series A-1 Warrants and Series B-1 Warrants of the Company, and (iii) a non-qualified stock option to purchase up to 2,056,049 shares of Common Stock, with an exercise price equal to the Closing Price, which shall vest in 48 substantially equal monthly installments, subject to the achievement of certain performance-based vesting conditions.
The inducement awards to Mr. Iwicki were granted as a material inducement to his employment and were approved by the Board in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted outside of the Company’s 2020 Equity Incentive Plan.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for Cardiopulmonary disease. Inhibikase’s cardiopulmonary disease portfolio is led by IkT-001Pro, a prodrug of imatinib mesylate, for PAH that will deliver imatinib in a form that the Company believes will provide a better patient experience with fewer on-dosing side-effects.
Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use X, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities, or future events or conditions; expected use of proceeds from the Company’s recent offering; and expectations regarding the anticipated contribution of Mr. Iwicki and the members of our board of directors to our operations and progress. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the Company’s ability to commence and execute a Phase 2b ‘702’ trial to evaluate IkT-001Pro as a treatment for PAH, as well as such other factors that are included in the Company’s periodic reports on the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and in other documents that the Company files with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Investor Relations:
Michael Moyer
Life Science Advisors
617-308-4306
mmoyer@lifesciadvisors.com
FAQ
Who is the new CEO of Inhibikase Therapeutics (IKT) and when did they start?
How many stock options were granted to IKT's new CEO Mark Iwicki?
What is the current status of IKT-001Pro development?
Who is the new Chairman of the Board for Inhibikase (IKT)?
